2 min readFinding Leukaemia’s Weakness Using Genome-Wide CRISPR Technology

La Jolla, CA — A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukaemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. 

“We used CRISPR technology to carry out a genome-wide screen in leukaemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukaemia growth and find new vulnerabilities that can be targeted in this disease,” said senior author Dr. Tannishtha Reya, professor in the departments of Pharmacology and Medicine. “The study also shows, for the first time, that whole genome CRISPR-based screens can in fact be carried out in a manner that is much more physiologically relevant: using primary cancer cells, and in the setting of the native microenvironment.”

Reporting in the April 20, 2020 online edition of the journal Nature Cancer, Reya and colleagues identified RNA-binding proteins — which normally control how, when and if cells make certain proteins — as a key class of proteins that sustain and protect drug-resistant leukaemia stem cells. The authors focused on Staufen2 (Stau2), a relatively understudied member of the RNA-binding protein family that was previously only known to control brain and nervous system development.

This work was carried out in collaboration with UC San Diego investigators Drs. Gene Yeo and Anjana Rao, and was conducted by lead author Dr. Jeevisha Bajaj, while she was a postdoctoral fellow at UC San Diego in the Reya lab. Bajaj subsequently joined the University of Rochester Medical Center as assistant professor of biomedical genetics and a researcher at the Wilmot Cancer Institute.

The team developed a mouse model in which Stau2 was genetically deleted and found that loss of this protein led to a profound reduction in leukaemia growth and propagation, and markedly improved overall survival in mouse models. Stau2 was also required for continued growth of primary tissue samples of patients with leukaemia, indicating a conserved dependence in the human disease. 

“We are particularly excited about this work because, to our knowledge, this is the first demonstration that Staufen2 is a key dependency in any cancer,” said Reya, who is a member of Moores Cancer Center and the Sanford Consortium for Regenerative Medicine. 

To understand how Stau2 controls cancer, researchers undertook a genome-scale computational analysis of its targets through RNA-Seq and eCLIP-Seq. This led to the discovery that this protein controls key oncogenes, such as Ras, and epigenetic regulators, such as the LSD/KDM family of proteins, which are critical drug targets being tested against leukaemia and other cancers. 

According to the National Cancer Institute, approximately 1.5 percent of men and women will be diagnosed with leukaemia at some point during their lifetimes. While chronic myeloid leukaemia (CML) can be controlled with targeted therapies, this disease can be lethal if it advances or is diagnosed in an acute “blast” phase. The findings also have implications for acute myeloid leukaemia (AML) and other blood cancers.

“This work will be particularly important for the discovery of new treatments,” said Bajaj. “Our genome-wide screen identified cellular signals critical for the growth of cancer, and in the future, this study will be useful to study the microenvironment, the area around the tumor that includes tissue, blood vessels and important molecular signals related to how the cancer behaves.”

Article adapted from a University of California San Diego news release.

Publication: An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukaemia. Bajaj, J et al. Nature Cancer (April 20, 2020): Click here to view.

aggressive chronic myeloid leukaemia, chronic myeloid leukaemia, CRISPR, Leukaemia, Stau2, Staufen2

Leave a Reply

© 2022 Mindzilla. All rights reserved.